Who is sponsoring NCT03852693?

NCT03852693 is sponsored by Insel Gruppe AG, University Hospital Bern.

What drugs are being tested in NCT03852693?

Interventions in NCT03852693: Histopathological review.

What condition does NCT03852693 study?

NCT03852693 studies Neuroendocrine Tumors of the Appendix.

Is NCT03852693 still recruiting?

NCT03852693 is currently completed. Last updated 13 November 2024.

Last reviewed 2024-11-13 · How we verify

NCT03852693: SurvivApp

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix

Completed Last updated 13 November 2024

What this trial tests

trial testing Histopathological review in Neuroendocrine Tumors of the Appendix in 278 participants. Completed in 30 August 2022.

Timeline

1 October 2020

Primary endpoint
30 August 2022

30 August 2022

Quick facts

Lead sponsor	Insel Gruppe AG, University Hospital Bern
Status	Completed
Study type	OBSERVATIONAL
Enrollment	278
Start date	1 October 2020
Primary completion	30 August 2022
Estimated completion	30 August 2022
Sites	1 location across Switzerland

Drugs / interventions tested

Histopathological review

Conditions studied

Neuroendocrine Tumors of the Appendix — all drugs for Neuroendocrine Tumors of the Appendix →

Sponsor

Insel Gruppe AG, University Hospital Bern

Who can join

Eligibility, any sex, with Neuroendocrine Tumors of the Appendix. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present project is to evaluate the frequency of distant metastases and clinically relevant relapse and mortality, respectively, of aNEN (Neuroendocrine Neoplasms of the Appendix) measuring 1 - 2 cm. The investigators hypothesize that the mortality rate of aNET (Neuroendocrine Tumors of the Appendix) measuring 1 - 2cm is less than 1%. Furthermore, the investigators hypothesize that regional lymph node metastases of aNET measuring 1 - 2 cm are clinically not relevant and are not associated with reduced survival. The investigators therefore hypothesize that oncological right-sided hemicolectomy has no impact on long-term survival after complete resection of aNET measuring 1 - 2 cm and that the malignant potential quo ad vitam of these tumors is lower than the risk of oncological hemicolectomy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study.
Nesti C, Bräutigam K, Benavent M, Bernal L, et al · · 2023 · cited 55× · PMID 36640790 · DOI 10.1016/s1470-2045(22)00750-1
An Update on Appendiceal Neuroendocrine Tumors.
Andrini E, Lamberti G, Alberici L, Ricci C, et al · · 2023 · cited 11× · PMID 37140773 · DOI 10.1007/s11864-023-01093-0

Verify or expand the search:

Other trials of Histopathological review

Trials testing the same drug.

NCT06787014 — Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and · recruiting

Other Insel Gruppe AG, University Hospital Bern trials

Trials by the same sponsor.

NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03852693 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
Last refreshed: 13 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03852693.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing